CXCL13/BLC/BCA-1 組換え体(リコンビナント)タンパク質 | Recombinant Human CXCL13/BLC/BCA-1

R&D Systems社製の高品質なCXCL13/BLC/BCA-1の組換え体タンパク質(Recombinant Human CXCL13/BLC/BCA-1)です。
※本製品は研究用です。研究用以外には使用できません。

※バルク包装品も承ります。お気軽にお問合せ下さい。

R&D Systems社組換え体タンパク質製品では通常ウシ血清アルブミン(BSA)をキャリアタンパク質として加えています。キャリアタンパク質を加えることで組換え体タンパク質の安定性が高まり、使用期限が長くなります。また、より濃度の低い溶液での保管も可能となります。CF製品はBSAが含まれない製品となります。一般的に細胞培養や、ELISAのスタンダードにはBSA含有製品を推奨しています。CF製品はBSAが影響してしまうアプリケーションに推奨されます。

Citations of cell biology reagents in peer reviewed literature can be used as a direct measure of product quality. They can also provide crucial insightinto their use under specialized or unique experimental conditions. Because of the importance published citations have to researchers, R&D Systems personnelmanually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but alsoprovides information about sample types, species, and experimental conditions.

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
Buggy JJ, Chen SS, Ponader S
Blood 2012 119:1182-9
Species: Human
Protein Application: Bioassay


Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.
Burton L, Chan E, Fridlyand J, Koeppen H, Li J, Lin E, Merchant M, Moffat J, Neve R, Peng J, Penuel E, Ribas A, Settleman J, Sosman J, Sutherlin DP, Wang Y, Wilson TR, Yan Y
Nature 2012 487:505-9
Species: Human
Protein Application: Bioassay


Changes in chemokines and chemokine receptor expression on tonsillar B cells upon Epstein-Barr virus infection.
Cagigi A, Ehlin-Henriksson B, Klein G, Liang W, Mowafi F, Nilsson A
Immunology 2009 127:549-57
Species: Human
Protein Application: Bioassay


CCL21 overexpressed on lymphatic vessels drives thymic hyperplasia in myasthenia.
Berrih-Aknin S, Bismuth J, Cizeron-Clairac G, Dartevelle P, de Rosbo NK, Le Panse R, Ruhlmann N, Shachar I, Zelman E
Ann. Neurol. 2009 66:521-31
Species: Human
Protein Application: Bioassay


Increased serum levels of the chemokine CXCL13 and up-regulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vasculitis.
Conteduca V, Dammacco F, Lauletta G, Montrone M, Sansonno D, Sansonno L, Troiani L, Tucci FA
Blood 2008 112:1620-7
Species: N/A
Protein Application: antibody absorption control


Loss of IL-7 receptor alpha on CD4+ T cells defines terminally differentiated B cell-helping effector T cells in a B cell-rich lymphoid tissue.
Kim CH, Lim HW
J. Immunol. 2007 179:7448-56
Species:
Protein Application: Bioassay


Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia.
Burger JA, Burkle A, Keating MJ, Niedermeier M, Schmitt-Graff A, Wierda WG
Blood 2007 110:3316-25
Species: Human
Protein Application: Bioassay


Hyaluronan-based polymer scaffold modulates the expression of inflammatory and degradative factors in mesenchymal stem cells: Involvement of Cd44 and Cd54.
Caplan AI, Cavallo C, Cristino S, Facchini A, Lisignoli G, Piacentini A
J. Cell. Physiol. 2006 207:364-73
Species: N/A
Protein Application: ELISA Standard


Distinct transcriptional programs activated by interleukin-10 with or without lipopolysaccharide in dendritic cells: induction of the B cell-activating chemokine, CXC chemokine ligand 13.
Allavena P, Bazzoni F, Bianchi G, Locati M, Mantovani A, Martinez FO, Nebuloni M, Perrier P, Sozzani S, Vago G
J. Immunol. 2004 172:7031-42
Species: Human
Protein Application: Bioassay


Expression of functional CCR and CXCR chemokine receptors in podocytes.
Burger JA, Exner M, Huber TB, Kerjaschki D, Pavenstadt H, Reinhardt HC, Saleem MA
J. Immunol. 2002 168:6244-52
Species: Human
Protein Application: Bioassay